Noxopharm Limited

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines. It has three active drug development programs: two innovative technology platforms SofraTM (mRNA vaccines, inflammation and autoimmunity) and ChromaTM (oncology) which provide the basis for active development of a growing pipeline of new proprietary drugs, as well as its clinical drug candidate Veyonda. The company has unique proprietary technology aimed at making mRNA vaccines safer to take by reducing side effects while reducing manufacturing costs for vaccine producers. Noxopharm also has a major shareholding in the...

Psoriasis,lupus,chronic inflammation,pancreatic cancer,oligonucleotides,mrna vaccines,mrna therapeutics ,autoimmune disease,sle,tlr7,tlr8,tbk1,preclinical research,oncology,drug development,biotechnology,nucleic acids,strategic partnerships,pharmaceutical,and small molecule

Noxopharm limited operates in the Biotechnology research industry.

Noxopharm limited's revenue is 11m - 100m

Noxopharm limited has 11 - 50 employees.